Patent: 9,539,257
✉ Email this page to a colleague
Summary for Patent: 9,539,257
Title: | Method of treating cancer |
Abstract: | Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923. |
Inventor(s): | Bing; Nan (Research Triangle Park, NC), Briley; Linda Perry (Research Triangle Park, NC), Budde; Laura R. (Research Triangle Park, NC), Cox; Charles J. (Stevenage, GB), Spraggs; Colin F. (Stevenage, GB) |
Assignee: | Novartis AG (CH) |
Application Number: | 14/634,052 |
Patent Claims: | see list of patent claims |
Details for Patent 9,539,257
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |